In silico designing of domain B selective gyrase inhibitors for effective treatment of resistant tuberculosis.
Sign Up to like & getrecommendations! Published in 2018 at "Tuberculosis"
DOI: 10.1016/j.tube.2018.08.005
Abstract: One of the major mechanisms followed by the therapeutic agents to target the causative organism of TB, Mycobacterium tuberculosis, involves disruption of its DNA replication cycle. The process of replication involves two steps, i.e., breakage… read more here.
Keywords: selective gyrase; gyrase inhibitors; gyrb domain; tuberculosis ... See more keywords
A Mycobacterium tuberculosis NBTI DNA Gyrase Inhibitor Is Active against Mycobacterium abscessus
Sign Up to like & getrecommendations! Published in 2021 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01514-21
Abstract: Fluoroquinolones—the only clinically used DNA gyrase inhibitors—are effective against tuberculosis (TB) but are in limited clinical use for nontuberculous mycobacteria (NTM) lung infections due to intrinsic drug resistance. We sought to test alternative DNA gyrase… read more here.
Keywords: tuberculosis; abscessus; gyrase; gyrase inhibitors ... See more keywords
Assessment of Structural Basis for Thiazolopyridine Derivatives as DNA Gyrase-B Inhibitors.
Sign Up to like & getrecommendations! Published in 2023 at "Current drug discovery technologies"
DOI: 10.2174/1570163820666230222151558
Abstract: BACKGROUND Tuberculosis (TB) is one of the leading causes of death in the post-Covid-19 era. It has been observed that there is a devastating condition with a 25-30% increase in TB patients. DNA gyrase B… read more here.
Keywords: dna gyrase; thiazolopyridine derivatives; derivatives dna; qsar ... See more keywords